Prolonged metformin use effective for Type 2 diabetes, study finds
PORTLAND, Ore. The sooner people with diabetes start taking metformin, the longer the drug remains effective, according to a Kaiser Permanente study published in the March issue of Diabetes Care, a journal of the American Diabetes Association.
Metformin is recommended as a first-line agent in the treatment of Type 2 diabetes, but its efficacy may deplete among patients. To determine how the drug influences patients’ control of their diabetes, researchers attained electronic health records to follow nearly 1,800 people with diabetes in Kaiser Permanente’s health plan in Washington and Oregon for up to five years. Metformin failed at a rate of only 12% a year for the patients who began taking it within three months of diagnosis, compare with a failure rate of 21.4% per year for patients who started taking metformin one to two years after diagnosis, and 21.9% per year for those who didn’t start taking the drug until three years after they were diagnosed.
In the study, patients were considered to have failed metformin when their hemoglobin A1C — a test that monitors glucose control — went above 7.5% or when they started taking a second anti-hyperglycemic agent. Only patients who initially controlled blood sugar (to less than 7% on the A1C test) with metformin were included in the study.
Study authors Jonathan Brown, PhD, MPP, and Gregory Nichols, PhD, from the Kaiser Permanente Center for Health Research in Portland, Ore., and Christopher Conner, PharmD, PhD, from Novo Nordisk, said the results of the study were welcomed news for newly diagnosed patients.
“This is an important finding for the 30 million people world-wide who are diagnosed with Type 2 diabetes every year. The sooner they start taking metformin, the better and longer it seems to work,” said the study’s lead author Brown said. “This study suggests that to gain full benefit from metformin, patients should start taking it as soon as they find out they have diabetes.”
No comments found
RediClinic offering Latisse consultations
HOUSTON RediClinic, which operates 22 retail health clinics inside select H-E-B stores in the Greater Houston and Austin area, now is offering Latisse, an FDA-approved prescription treatment to grow lashes.
Latisse is a prescription treatment for hypotrichosis used to grow eyelashes. Eyelash hypotrichosis is another name for not having enough eyelashes or eyelashes that are inadequate. The topical solution must be applied each night on the skin of the upper eyelid margins at the base of the eyelashes. Results are gradual and peak after 12 to 16 weeks.
RediClinic is offering Latisse consultations for $69.
Good to know this. Many women would love to consult first before jumping to using Latisse or buy latisse. It is always good to know first if you are okay with anything you are going to take.
Where exactly can I find this clinic? I want to consult in a very prestigious clinic first before I will purchase and use Latisse. Just want to make sure. Shay Arrellin buy latisse
Bristol-Myers Squibb, AstraZeneca announce postmarketing study for Onglyza
WILMINGTON, Del. Two drug makers hope to find out how well a diabetes drug works in treating patients who run the risk of developing cardiovascular diseases in a post-marketing study announced Tuesday.
Bristol-Myers Squibb and AstraZeneca announced the start of a phase 4 study of 12,000 patients with Type 2 diabetes treated with the drug Onglyza (saxagliptin). The placebo-controlled study, called SAVOR-TIMI 53, will take place over a five-year period and follow patients who have a history of previous cardiovascular problems or multiple risk factors for vascular disease, with the goal of determining whether adding Onglyza to their current standard of care will reduce their risk of cardiovascular death, heart attack or stroke.
The Food and Drug Administration approved Onglyza in July 2009.
No comments found